Combination of copeptin, placental growth factor and total ANNEXIN V (cas 136107-94-3) microparticles for prediction of preeclampsia at 10–14 weeks of gestation

Add time:09/03/2019    Source:sciencedirect.com

IntroductionPreeclampsia (PE) remains to be an enigmatic puzzle for clinicians and researchers perplexing them for decades. As delivery remains only choice of treatment, early prediction of PE will offer timely therapeutic invention and hence extensive research efforts have been put in identification of biomarkers which will facilitate early prediction of PE.

We also recommend Trading Suppliers and Manufacturers of ANNEXIN V (cas 136107-94-3). Pls Click Website Link as below: cas 136107-94-3 suppliers

Prev:Full Length ArticleStable thrombus formation on irradiated microvascular endothelial cells under pulsatile flow: Pre-testing ANNEXIN V (cas 136107-94-3)-thrombin conjugate for treatment of brain arteriovenous malformations
Next:Anti-ANNEXIN V (cas 136107-94-3) antibodies: are they prothrombotic?)